#United States #Class Action #San Francisco #Corcept Therapeutics #FDA Rejection

Corcept Therapeutics Faces Securities Class Action After FDA and Patent Setbacks

On March 18, 2026, Hagens Berman, a notable law firm representing shareholder rights, notified investors of a securities class action involving Corcept Therapeutics Incorporated (NASDAQ: CORT). This alert centers around significant developments concerning the company's lead drug candidate, relacorilant, which recently faced severe setbacks, including an FDA rejection and a critical federal court patent loss.

Background of the Case

The lawsuit, titled Allegheny County Employees' Retirement System v. Corcept Therapeutics Inc., et al., was filed in the Northern District of California. It aims to recover losses for all individuals and entities that purchased Corcept common stock during a specific period from October 31, 2024, to December 30, 2025. The law firm emphasized that shareholders suffering substantial losses should act promptly, as the deadline to apply for lead plaintiff status is set for April 21, 2026.

Hagens Berman’s Reed Kathrein, the partner leading the investigation, described the essence of the case as being rooted in a problematic information gap. This gap emerged between what Corcept disclosed publicly and the warnings issued privately by the FDA regarding the reliability of their clinical data.

Allegations Unfold

The complaint highlights several serious allegations against Corcept:
1. Concealment of FDA Concerns: It is alleged that during discussions with the FDA leading up to the drug’s submission in early 2025, the agency repeatedly expressed concerns over the company's clinical evidence, deeming it insufficient to support a New Drug Application (NDA).
2. Misleading Claims: Despite being aware of the FDA’s skepticism about the trial results, Corcept continued to project a positive narrative about the Phase 3 trials, presenting data that they allegedly knew to be flawed.
3. The CRL Incident: On December 31, 2025, Corcept disclosed it had received a Complete Response Letter (CRL) from the FDA. This letter indicated that the FDA could not ascertain any favorable risk-benefit profile due to concerns over insufficient evidence. Such news resulted in a drastic drop in Corcept's stock, plummeting by approximately 50% from $70.20 to $34.80 in one day—erasing nearly $2.5 billion in market value.

The lawsuit argues that this chain of events constitutes not just misinformation but potentially a breach of fiduciary duties to shareholders who placed their trust in Corcept's management.

Implications for Corcept Investors

Investors are being urged to evaluate their options carefully in the wake of these developments. Hagens Berman has highlighted the risks associated with failing to act—those who may have experienced financial losses are encouraged to reach out to the firm to discuss their legal rights and the potential for participation in the class action.

Important Dates

• - Class Period: October 31, 2024 - December 30, 2025
• - Lead Plaintiff Deadline: April 21, 2026

It is vital for shareholders to recognize these deadlines and consider their legal avenues before it's too late.

Whistleblower Information

For those who possess non-public information related to Corcept and wish to aid in the investigation, Hagens Berman has noted the availability of the SEC Whistleblower program, which offers rewards up to 30% of successful recoveries.

Conclusion

As the case unfolds, the implications of Corcept’s management decisions, disclosures, and the subsequent actions of the FDA will be under scrutiny. Investors in Corcept are strongly encouraged to stay informed and consider their positions seriously in light of these recent legal challenges. To learn more or to partake in the class action, interested parties can visit Hagens Berman's dedicated CORT Case Page.

For queries, potential investors can contact Reed Kathrein directly at 844-916-0895 or via email at [email protected].